Compare SID & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | NNNN |
|---|---|---|
| Founded | 1941 | 2021 |
| Country | Brazil | Germany |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2002 | N/A |
| Metric | SID | NNNN |
|---|---|---|
| Price | $1.28 | $26.05 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.40 | N/A |
| AVG Volume (30 Days) | ★ 7.6M | 21.8K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.38 | N/A |
| Revenue Next Year | $2.49 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $5.91 |
| 52 Week High | $2.20 | $55.65 |
| Indicator | SID | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 56.03 |
| Support Level | N/A | $19.53 |
| Resistance Level | $1.64 | $30.70 |
| Average True Range (ATR) | 0.06 | 2.17 |
| MACD | 0.02 | 0.54 |
| Stochastic Oscillator | 84.21 | 71.99 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.